Report : South and Central America Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

Treatment Segment to Dominate South & Central America Non-Alcoholic Steatohepatitis market Forecast to 2028 during 2019–2028

 

According to a new market research study on the South & Central America Non-Alcoholic Steatohepatitis market Forecast to 2028 –– by product, application, sales channel and countries is expected to reach US$ 303.88 million by 2028 from US$ 44.76 million in 2021. The market is estimated to grow at a CAGR of 31.5% from 2021 to 2028. The report provides trends prevailing in the South & Central America Non-Alcoholic Steatohepatitis market along with the drivers and restraints pertaining to the market growth.Rising prevalence of NASH is the major factor driving the growth of the South & Central America Non-Alcoholic Steatohepatitis market. However, issues associated with stringent regulations related to Non-Alcoholic Steatohepatitis the growth of South & Central America Non-Alcoholic Steatohepatitis market.

 

The South & Central America Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the South & Central America Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period.Based on application the South & Central America Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated South & Central America Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel the South & Central America Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated South & Central America Non-Alcoholic Steatohepatitis market in 2020. Based on country, the South & Central America Non-Alcoholic Steatohepatitis market segmented into Brazil, Argentina and RoSCAM. The Brazil is dominated the South & Central America Non-Alcoholic Steatohepatitis   market in 2020.

 

Cadila Pharmaceutical,Intercept Pharmaceutical,Novartis AG,Galmed Pharmaceutical,GENFIT,Siemens Healthineers AG and Laboratory Corporation of America are among the leading companies in the South & Central America  Non-Alcoholic Steatohepatitis  market. For instance, Mar-2022 Novartis announced that it has signed agreement with Carisma Therapeuticsto manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in dynamic market.

 

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: sales@businessmarketinsights.com 

 

Download Free PDF Brochure